The previous study has unveiled that the co-administration of ursolic acid and sorafenib exhibits a synergistic impact by upregulating ROS levels and downregulating the expression of SLC7A11 in gastric cancer and colon cancer cells 20. This evidence concerns the gene SLC7A11 and gastric cancer.